Crossmark

Randomized Phase 3 Trial of Ombitasvir/Paritaprevir/Ritonavir and Ribavirin for Hepatitis C Virus Genotype 2-Infected Japanese Patients

Crossref DOI link: https://doi.org/10.1007/s12325-017-0506-y

Published Online: 2017-05-23

Published Print: 2017-06

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Sato, Ken

Chayama, Kazuaki

Alves, Katia

Toyoda, Hidenori

Suzuki, Fumitaka

Kato, Koji

Rodrigues, Lino Jr.

Zhang, Xinyan

Setze, Carolyn

Pilot-Matias, Tami

Burroughs, Margaret

Redman, Rebecca

Kumada, Hiromitsu
Funding

Funding for this research was provided by:

AbbVie
License Information

Text and Data Mining valid from 2017-05-23
More Information

Article History

Received: 23 August 2016

First Online: 23 May 2017